Have a feature idea you'd love to see implemented?
Let us know!
LAB Standard BioTools Inc
Price (delayed)
$1.62
Market cap
$603.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.71
Enterprise value
$481.89M
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions
Highlights
Standard BioTools's gross profit has soared by 57% YoY and by 19% from the previous quarter
Standard BioTools's revenue has increased by 48% YoY and by 14% from the previous quarter
LAB's quick ratio is up by 20% YoY but it is down by 3.4% from the previous quarter
The company's net income has shrunk by 65% YoY and by 5% QoQ
Standard BioTools's equity has decreased by 4.1% QoQ
Key stats
What are the main financial stats of LAB
Market
Valuations
Earnings
Shares outstanding
372.26M
Market cap
$603.06M
Enterprise value
$481.89M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.23
Price to sales (P/S)
3.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.09
Revenue
$155.9M
EBIT
-$123.35M
EBITDA
-$104.99M
Free cash flow
-$148.51M
Per share
Balance sheet
Liquidity
EPS
-$0.71
Free cash flow per share
-$0.4
Book value per share
$1.32
Revenue per share
$0.42
TBVPS
$1.49
Total assets
$681.54M
Total liabilities
$192.21M
Debt
$89.47M
Equity
$489.33M
Working capital
$332.99M
Debt to equity
0.18
Current ratio
3.76
Quick ratio
3.36
Net debt/EBITDA
1.15
Margins
Efficiency
Dividend
EBITDA margin
-67.3%
Gross margin
48.6%
Net margin
-79.9%
Operating margin
-105.1%
Return on assets
-27.4%
Return on equity
-47.8%
Return on invested capital
-46.2%
Return on capital employed
-22%
Return on sales
-79.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LAB stock price
How has the Standard BioTools stock price performed over time
Intraday
0.62%
1 week
-4.71%
1 month
-13.83%
1 year
-29.57%
YTD
-26.7%
QTD
-16.06%
Financial performance
How have Standard BioTools's revenue and profit performed over time
Revenue
$155.9M
Gross profit
$75.71M
Operating income
-$163.81M
Net income
-$124.59M
Gross margin
48.6%
Net margin
-79.9%
LAB's operating income has plunged by 115% YoY and by 7% from the previous quarter
The company's net income has shrunk by 65% YoY and by 5% QoQ
Standard BioTools's gross profit has soared by 57% YoY and by 19% from the previous quarter
Standard BioTools's revenue has increased by 48% YoY and by 14% from the previous quarter
Growth
What is Standard BioTools's growth rate over time
Valuation
What is Standard BioTools stock price valuation
P/E
N/A
P/B
1.23
P/S
3.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.09
Standard BioTools's EPS has increased by 26% YoY and by 22% from the previous quarter
Standard BioTools's equity has decreased by 4.1% QoQ
The P/S is 48% above the 5-year quarterly average of 2.6 but 10% below the last 4 quarters average of 4.3
Standard BioTools's revenue has increased by 48% YoY and by 14% from the previous quarter
Efficiency
How efficient is Standard BioTools business performance
The ROE has increased by 41% QoQ
The company's return on assets fell by 32% YoY but it rose by 11% QoQ
The return on invested capital has declined by 25% year-on-year but it has increased by 6% since the previous quarter
Standard BioTools's ROS has decreased by 13% YoY but it has increased by 8% from the previous quarter
Dividends
What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LAB.
Financial health
How did Standard BioTools financials performed over time
LAB's total assets has surged by 101% year-on-year but it is down by 3.8% since the previous quarter
LAB's quick ratio is up by 20% YoY but it is down by 3.4% from the previous quarter
The debt is 82% smaller than the equity
LAB's debt to equity has soared by 124% year-on-year
The debt has declined by 10% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.